II Ibero-Latin American Forum of AATD
On December 14, 2020, the II Ibero-Latin American Forum of DAAT (IBLA-AATD) took place.
In this II Ibero-Latin American Forum on Alpha-1 Antitrypsin Deficiency, the current situation of diagnosis and treatment of AATD in our environment is addressed. However, given the pandemic situation, it has been held in virtual format.
United for Advancement in Medical Research
The Spanish Network for Alpha-1 Antitrypsin Deficiency (REDAAT) has promoted the creation of the II Ibero-Latin American Forum on Alpha-1 Antitrypsin Deficiency. The coordinators of the event have been:
- Francisco Casas (Spain)
- Alejandra Rey (Uruguay)
- Michael Campos (Peru-USA)
Speakers and congressmen from Argentina, Brazil, Chile, Colombia, Ecuador, Peru, Uruguay, Portugal and Spain have participated in the II Ibero-Latin American Forum of AATD, working to improve the diagnosis and treatment of patients with AATD.
The General objective of the II Ibero-American Forum of AATD is to share knowledge and experience about the AATD.
In general terms, our goal is to advance towards a better diagnosis of this underdiagnosed disease, especially in Latin America, as well as to improve the care of these patients and their families.
In particular, the objectives set for the Forum are:
- Strengthen ties between professionals in Spain and Latin America interested in the DAAT.
- Know the real situation of AATD in each of the countries, specifically detecting the needs and factors related to underdiagnosis, in order to direct actions that help alleviate this delay.
- To lay the foundations to coordinate an international AATD screening program, using the new Progenika technology.
- Validate the best case search strategies and logistics for the screening program with Progenika to arrive at a consensual diagnostic algorithm.
- Promote collaboration in national or international multicenter research projects that may arise from the forum.
- Discuss current aspects of the AATD in Latin America and Spain, from the clinical point of view, to allow an active interaction between attendees on the challenges and needs not covered in the diagnosis of the AATD.
As a result, in this II Ibero-American Forum of DAAT, 3 thematic blocks have been established to discuss the experience with Progenika, the EARCO initiative and treatment with intravenous AAT.
Block I
Svezda Drobnic has spoken to us about different aspects of AAT preparation. María Torres and Martín Eduardo Fernández have spoken about the experience of treatment with AAT in Day Hospital and Home Care, respectively.
Block II
Marc Miravitlles has updated information on the EARCO initiative (European Alpha-1 Research Collaboration) and the projects that are being carried out.
Block III
Svezda Drobnic has spoken to us about different aspects of AAT preparation. María Torres and Martín Eduardo Fernández have spoken about the experience of treatment with AAT in Day Hospital and Home Care, respectively.
